Joshua R. Disbrow Purchases 15,000 Shares of Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock

Aytu BioPharma, Inc. (NASDAQ:AYTU) CEO Joshua R. Disbrow purchased 15,000 shares of the business’s stock in a transaction dated Friday, February 28th. The stock was purchased at an average price of $1.30 per share, for a total transaction of $19,500.00. Following the completion of the acquisition, the chief executive officer now owns 86,591 shares of the company’s stock, valued at approximately $112,568.30. This represents a 20.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Aytu BioPharma Price Performance

Shares of Aytu BioPharma stock opened at $1.26 on Wednesday. The business’s 50 day simple moving average is $1.57 and its 200 day simple moving average is $1.88. Aytu BioPharma, Inc. has a 52-week low of $1.23 and a 52-week high of $3.45. The firm has a market cap of $7.77 million, a PE ratio of -0.87 and a beta of -1.45. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 0.98.

Aytu BioPharma (NASDAQ:AYTU) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.28) earnings per share for the quarter. Aytu BioPharma had a negative return on equity of 19.30% and a negative net margin of 7.62%.

Institutional Investors Weigh In On Aytu BioPharma

An institutional investor recently raised its position in Aytu BioPharma stock. Stonepine Capital Management LLC lifted its holdings in shares of Aytu BioPharma, Inc. (NASDAQ:AYTU) by 6.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 500,958 shares of the company’s stock after buying an additional 28,489 shares during the period. Aytu BioPharma comprises 0.7% of Stonepine Capital Management LLC’s holdings, making the stock its 25th largest position. Stonepine Capital Management LLC owned approximately 8.15% of Aytu BioPharma worth $1,177,000 as of its most recent SEC filing. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.